• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The US Preventive Services Task Force 2017 Draft Recommendation Statement on Screening for Prostate Cancer: An Invitation to Review and Comment.

作者信息

Bibbins-Domingo Kirsten, Grossman David C, Curry Susan J

机构信息

University of California, San Francisco.

Kaiser Permanente Washington Health Research Institute, Seattle, Washington.

出版信息

JAMA. 2017 May 16;317(19):1949-1950. doi: 10.1001/jama.2017.4413.

DOI:10.1001/jama.2017.4413
PMID:28397958
Abstract
摘要

相似文献

1
The US Preventive Services Task Force 2017 Draft Recommendation Statement on Screening for Prostate Cancer: An Invitation to Review and Comment.美国预防服务工作组2017年关于前列腺癌筛查的建议声明草案：邀请审查与评论。
JAMA. 2017 May 16;317(19):1949-1950. doi: 10.1001/jama.2017.4413.
2
Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.基于前列腺特异性抗原的前列腺癌筛查：美国预防服务工作组的证据报告和系统评价。
JAMA. 2018 May 8;319(18):1914-1931. doi: 10.1001/jama.2018.3712.
3
Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.前列腺癌筛查：美国预防服务工作组推荐声明。
JAMA. 2018 May 8;319(18):1901-1913. doi: 10.1001/jama.2018.3710.
4
Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force.前列腺癌筛查：美国预防服务工作组的证据回顾。
Ann Intern Med. 2011 Dec 6;155(11):762-71. doi: 10.7326/0003-4819-155-11-201112060-00375. Epub 2011 Oct 7.
5
Trends in Prostate-Specific Antigen Screening Since the Implementation of the 2012 US Preventive Services Task Force Recommendations.自 2012 年美国预防服务工作组建议实施以来，前列腺特异性抗原筛查的趋势。
Eur Urol Focus. 2018 Dec;4(6):1002-1004. doi: 10.1016/j.euf.2017.02.004. Epub 2017 Feb 22.
6
PSA Screening for Prostate Cancer.前列腺癌的前列腺特异性抗原筛查
Am Fam Physician. 2015 May 1;91(9):Online.
7
Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.前列腺癌筛查：针对美国预防服务工作组审查的事实、统计数据及解读
J Clin Oncol. 2012 Jul 20;30(21):2581-4. doi: 10.1200/JCO.2011.40.4327. Epub 2012 Jun 18.
8
Grading the new US Preventive Services Task Force prostate cancer screening recommendation.对美国预防服务工作组新的前列腺癌筛查建议进行分级。
JAMA. 2011 Dec 28;306(24):2715-6. doi: 10.1001/jama.2011.1893.
9
PSA test not recommended by Canadian Task Force.加拿大特别工作组不建议进行前列腺特异性抗原（PSA）检测。
Lancet Oncol. 2014 Dec;15(13):e589. doi: 10.1016/S1470-2045(14)71111-8. Epub 2014 Oct 31.
10
Five-year downstream outcomes following prostate-specific antigen screening in older men.老年男性前列腺特异性抗原筛查后的 5 年随访结果。
JAMA Intern Med. 2013 May 27;173(10):866-73. doi: 10.1001/jamainternmed.2013.323.

引用本文的文献

1
Medical Mistrust on Prostate Cancer Screening: A mixed method study among African Americans, Caribbean immigrants and African immigrants.对前列腺癌筛查的医疗不信任：一项针对非裔美国人、加勒比移民和非洲移民的混合方法研究。
Med Res Arch. 2024 Aug;12(8). doi: 10.18103/mra.v12i8.5727. Epub 2024 Aug 31.
2
Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study.尿路上皮病理学家间 MRI 靶向活检的预期影响对 ProScreen 前列腺癌筛查试验：一项试验前验证研究。
World J Urol. 2024 Apr 6;42(1):217. doi: 10.1007/s00345-024-04898-2.
3
The complex interplay of modifiable risk factors affecting prostate cancer disparities in African American men.
影响非裔美国男性前列腺癌差异的可改变风险因素的复杂相互作用。
Nat Rev Urol. 2024 Jul;21(7):422-432. doi: 10.1038/s41585-023-00849-5. Epub 2024 Feb 2.
4
Racial disparity in the genomics of precision oncology of prostate cancer.前列腺癌精准肿瘤学的基因组学中的种族差异。
Cancer Rep (Hoboken). 2023 Sep;6 Suppl 1(Suppl 1):e1867. doi: 10.1002/cnr2.1867. Epub 2023 Aug 10.
5
Single test-based diagnosis of multiple cancer types using Exosome-SERS-AI for early stage cancers.基于外泌体 SERS-AI 的单一检测用于多种癌症类型的早期癌症诊断。
Nat Commun. 2023 Mar 24;14(1):1644. doi: 10.1038/s41467-023-37403-1.
6
Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US.美国低危前列腺癌管理中主动监测应用的时间趋势和变化。
JAMA Netw Open. 2023 Mar 1;6(3):e231439. doi: 10.1001/jamanetworkopen.2023.1439.
7
Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection.用于侵袭性前列腺癌检测的尿液前列腺特异性抗原和血清前列腺特异性抗原
Cancers (Basel). 2023 Feb 2;15(3):960. doi: 10.3390/cancers15030960.
8
A Nationwide Study of Differences in Surgical Treatment Rates and Oncological Outcomes for Prostate Cancer according to Economic Status and Region.一项基于经济状况和地区的前列腺癌手术治疗率和肿瘤学结局差异的全国性研究。
Cancer Res Treat. 2023 Apr;55(2):652-658. doi: 10.4143/crt.2022.893. Epub 2022 Dec 12.
9
Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.英国前列腺癌筛查的成本效益分析：基于 CAP 试验的决策模型分析。
Pharmacoeconomics. 2022 Dec;40(12):1207-1220. doi: 10.1007/s40273-022-01191-1. Epub 2022 Oct 6.
10
Copy number variation of urine exfoliated cells by low-coverage whole genome sequencing for diagnosis of prostate adenocarcinoma: a prospective cohort study.低覆盖度全基因组测序检测尿脱落细胞拷贝数变异在前列腺腺癌诊断中的应用：一项前瞻性队列研究。
BMC Med Genomics. 2022 May 5;15(Suppl 2):104. doi: 10.1186/s12920-022-01253-5.